KUALA LUMPUR, Dec 16 (Bernama) -- Bursa Malaysia extended its positive performance, closing higher for a fourth consecutive session, supported by improving local market sentiment underpinned by a firm domestic macroeconomic backdrop. At 5 pm, the FTSE Bursa Malaysia KLCI (FBM KLCI) rose 4.59 points, or 0.28 per cent, to 1,648.31, from Monday’s close of 1,643.72. The index had opened 0.95 of a point lower at 1,642.77, and moved between 1,636.50 and 1,648.71 throughout the trading session However, on the broader market, decliners beat gainers 699 versus 408. A further 520 counters were unchanged, 1,149 untraded and 12 suspended. Turnover rose to 2.59 billion units worth RM2.27 billion from 2.50 billion units worth RM2.16 billion on Monday.
Key Takeaway
Pre-market trade shows a sharp split between earnings-driven winners and guidance-related laggards. Small caps benefited from insider buying and dividends, while large-cap tech and pharma names faced pressure from weaker outlooks. Expect heightened volatility into the open as traders weigh growth momentum against valuation risks.
Major Gainers
BrilliA (BRIA.US) +110% after declaring a special cash dividend of $0.133 per share
Bolt Projects (BSLK.US) +49% following insider purchases disclosed in Form 4 filings
HWH International (HWH.US) +27% after trading resumed from a circuit breaker halt
Biodesix (BDSX.US) +25% on director’s $1.5m share purchase
American Eagle (AEO.US) +24% after stronger-than-expected Q2 earnings
Credo Technology (CRDO.US) +12% after Stifel raised its target price to $155 from $130
Asana (ASAN.US) +6% on solid Q2 results and raised FY2026 guidance
Hewlett Packard Enterprise (HPE.US) +5% after earnings beat and upgraded outlook
NuScale Power (SMR.US) +4% on landmark SMR capacity deal with TVA
Oscar Health (OSCR.US) +3% after reaffirming FY2025 sales guidance
Major Decliners
Neonode (NEON.US) -81% after Samsung patent settlement valued at $15–20m fell short of expectations
ALT5 Sigma (ALTS.US) -16% on launch turbulence and supply concerns
Figma (FIG.US) -15% following first post-IPO earnings with EPS miss and slower growth guidance
C3.ai (AI.US) -14% after revenue/EPS miss, CEO change, and withdrawn guidance
Sanofi (SNY.US) -8% after late-stage trial disappointment for amlitelimab in atopic dermatitis
Salesforce (CRM.US) -7% on weaker Q3 revenue guidance
GitLab (GTLB.US) -6% after Wells Fargo cut its price target to $55 from $60
American Bitcoin (ABTC.US) -4% on concerns from mining expansion
NIO (NIO.US) -4% as reduced NEV tax incentives next year weigh on demand outlook
SharpLink Gaming (SBET.US) -3% after announcing equity awards for new co-CEO
Analyst View
Market sentiment remains highly earnings-sensitive. Small caps are reacting strongly to insider activity and shareholder returns, while tech and biotech show downside risk on guidance misses. With the Fed meeting in mid-September and jobs data due Friday, traders should expect elevated volatility and sector rotation.
Comments
Post a Comment